...
首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets.
【24h】

A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets.

机译:大肠癌基因功能验证的基因组策略可确定潜在的治疗靶标。

获取原文
获取原文并翻译 | 示例
           

摘要

Genes that are highly overexpressed in tumor cells can be required for tumor cell survival and have the potential to be selective therapeutic targets. In an attempt to identify such targets, we combined a functional genomics and a systems biology approach to assess the consequences of RNAi-mediated silencing of overexpressed genes that were selected from 140 gene expression profiles from colorectal cancers (CRCs) and matched normal mucosa. In order to identify credible models for in-depth functional analysis, we first confirmed the overexpression of these genes in 25 different CRC cell lines. We then identified five candidate genes that profoundly reduced the viability of CRC cell lines when silenced with either siRNAs or short-hairpin RNAs (shRNAs), i.e., HMGA1, TACSTD2, RRM2, RPS2 and NOL5A. These genes were further studied by systematic analysis of comprehensive gene expression profiles generated following siRNA-mediated silencing. Exploration of these RNAi-specific gene expression signatures allowed the identification of the functional space in which the five genes operate and showed enrichment for cancer-specific signaling pathways, some known to be involved in CRC. By comparing the expression of the RNAi signature genes with their respective expression levels in an independent set of primary rectal carcinomas, we could recapitulate these defined RNAi signatures, therefore, establishing the biological relevance of our observations. This strategy identified the signaling pathways that are affected by the prominent oncogenes HMGA1 and TACSTD2, established a yet unknown link between RRM2 and PLK1 and identified RPS2 and NOL5A as promising potential therapeutic targets in CRC.
机译:肿瘤细胞的生存可能需要在肿瘤细胞中高度过表达的基因,并且有可能成为选择性治疗靶标。为了确定此类靶标,我们结合了功能基因组学和系统生物学方法,以评估RNAi介导的过表达基因沉默的后果,该过表达基因选自结直肠癌(CRC)和匹配的正常黏膜的140个基因表达谱。为了鉴定用于深入功能分析的可靠模型,我们首先确认了这些基因在25种不同的CRC细胞系中的过表达。然后,我们确定了五个候选基因,这些基因在用siRNA或短发夹RNA(shRNA)沉默时会大大降低CRC细胞系的生存力,即HMGA1,TATSD2,RRM2,RPS2和NOL5A。通过系统分析在siRNA介导的沉默后产生的全面基因表达谱,进一步研究了这些基因。对这些RNAi特异性基因表达特征的探索使得可以鉴定出五个基因在其中运作的功能空间,并显示出丰富的癌症特异性信号传导途径,其中一些已知与CRC有关。通过在独立的一组原发性直肠癌中比较RNAi签名基因的表达及其各自的表达水平,我们可以概括这些已定义的RNAi签名,因此,建立了我们观察结果的生物学相关性。该策略确定了受显着癌基因HMGA1和TACSTD2影响的信号通路,在RRM2和PLK1之间建立了未知的联系,并将RPS2和NOL5A确定为有希望的CRC潜在治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号